bioAffinity Technologies
BIAF
14 hedge funds and large institutions have $973K invested in bioAffinity Technologies in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
13% more capital invested
Capital invested by funds: $863K → $973K (+$110K)
0% more ownership
Funds ownership: 0.11% → 0.12% (+0%)
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$178K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$22.5K |
| 4 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
+$10K |
| 5 |
Morgan Stanley
New York
|
+$7.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$49.6K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$49.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$20.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.03K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$1.02K |
BIAF Hedge Fund Activity: Q3 2024 in Review
14 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q3 2024, worth a combined $973K — up 13% from $863K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIAF and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $178K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $49.6K sold.
- 14 institutional investors held bioAffinity Technologies (BIAF) as of Q3 2024, down from 17 in Q2 2024.
- Funds reported $973K of bioAffinity Technologies stock for Q3 2024, up 13% quarter-over-quarter.
- 2 funds opened new bioAffinity Technologies positions in Q3 2024 and 5 closed out, a net change of -3 holders.
- The largest bioAffinity Technologies buyer in Q3 2024 was Vanguard Group, an estimated $178K added.
- The largest bioAffinity Technologies seller in Q3 2024 was Renaissance Technologies, an estimated $49.6K sold.
Based on aggregated 13F filings for Q3 2024.